A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms Alidial Study
- 05 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Jul 2020.
- 05 Aug 2019 Planned primary completion date changed from 5 Jun 2019 to 31 Dec 2019.
- 15 Oct 2018 Status changed from not yet recruiting to recruiting.